Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) Expected to Announce Earnings of -$0.64 Per Share

Equities research analysts forecast that Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) will post ($0.64) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Three analysts have made estimates for Crinetics Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.48) and the lowest estimate coming in at ($0.82). Crinetics Pharmaceuticals posted earnings per share of ($0.35) in the same quarter last year, which would suggest a negative year over year growth rate of 82.9%. The company is expected to announce its next quarterly earnings report on Wednesday, March 11th.

According to Zacks, analysts expect that Crinetics Pharmaceuticals will report full-year earnings of ($2.14) per share for the current year, with EPS estimates ranging from ($2.30) to ($1.90). For the next year, analysts anticipate that the firm will report earnings of ($2.78) per share, with EPS estimates ranging from ($3.12) to ($2.35). Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that that provide coverage for Crinetics Pharmaceuticals.

Crinetics Pharmaceuticals (NASDAQ:CRNX) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.60) EPS for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.03). Crinetics Pharmaceuticals had a negative return on equity of 29.27% and a negative net margin of 1,303.31%. The company had revenue of $0.51 million during the quarter, compared to the consensus estimate of $0.33 million.

Several equities analysts recently issued reports on CRNX shares. ValuEngine raised Crinetics Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Wednesday, October 2nd. Zacks Investment Research raised Crinetics Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, October 15th.

Shares of CRNX traded up $0.19 during mid-day trading on Friday, reaching $18.56. The company had a trading volume of 25,900 shares, compared to its average volume of 63,139. The company has a market capitalization of $457.62 million, a price-to-earnings ratio of -8.32 and a beta of 0.88. Crinetics Pharmaceuticals has a 52 week low of $14.33 and a 52 week high of $36.95. The company has a debt-to-equity ratio of 0.04, a quick ratio of 19.07 and a current ratio of 19.07. The firm has a 50-day moving average price of $17.11 and a 200 day moving average price of $20.83.

Hedge funds have recently added to or reduced their stakes in the stock. Marshall Wace North America L.P. bought a new position in Crinetics Pharmaceuticals in the 1st quarter valued at approximately $43,000. Tower Research Capital LLC TRC lifted its position in Crinetics Pharmaceuticals by 441.4% in the 3rd quarter. Tower Research Capital LLC TRC now owns 2,691 shares of the company’s stock valued at $40,000 after acquiring an additional 2,194 shares in the last quarter. JPMorgan Chase & Co. lifted its position in Crinetics Pharmaceuticals by 45.3% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,033 shares of the company’s stock valued at $75,000 after acquiring an additional 946 shares in the last quarter. TD Asset Management Inc. bought a new position in Crinetics Pharmaceuticals in the 2nd quarter valued at approximately $210,000. Finally, Citadel Advisors LLC bought a new position in Crinetics Pharmaceuticals in the 2nd quarter valued at approximately $295,000. 78.20% of the stock is currently owned by institutional investors and hedge funds.

About Crinetics Pharmaceuticals

Crinetics Pharmaceuticals, Inc, a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is CRN00808, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly.

Read More: When is a capital gain realized?

Get a free copy of the Zacks research report on Crinetics Pharmaceuticals (CRNX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Crinetics Pharmaceuticals (NASDAQ:CRNX)

Receive News & Ratings for Crinetics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crinetics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.